Eli Lilly Is Worth Buying Now: Q1 Strength, Durable GLP-1 Leadership, and Clear Upside
Eli Lilly's Q1 performance and the retatrutide clinical headline put the company in a class of its own. The stock is trading at $931.64 with a market cap near $880B, rich multiples but justified by blockbuster growth prospects and strong cash generation. This is a position trade: buy at market, stop at $870, target $1,100 over the next 180 trading …